Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 5/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584209 | 0.87 | GRIA4 (0.63) | GRIA4CTSLCTSBCTSSCTSK | |
| SCHEMBL6783719 | 0.87 | GRIA4 (0.63) | GRIA4CTSLCTSBCTSSCTSK | |
| SCHEMBL6787374 | 0.87 | GRIA4 (0.56) | GRIA4CTSLCTSBCTSSCTSK | |
| SCHEMBL6789814 | 0.85 | GRIA4 (0.60) | GRIA4CTSLCTSBCTSSCTSK | |
| SCHEMBL6788018 | 0.85 | GRIA4 (0.60) | GRIA4CTSLCTSBCTSSCTSK | |
| SCHEMBL6787350 | 0.85 | GRIA4 (0.64) | GRIA4CTSLCTSBCTSSCTSK | |
| SCHEMBL6783488 | 0.85 | GRIA4 (0.54) | GRIA4CTSLCTSBCTSSCTSK | |
| SCHEMBL6783013 | 0.84 | GRIA4 (0.59) | GRIA4CTSLCTSBCTSSCTSK | |
| SCHEMBL6789847 | 0.84 | GRIA4 (0.59) | GRIA4CTSLCTSBCTSSCTSK | |
| SCHEMBL7209225 | 0.84 | GRIA4 (0.59) | GRIA4CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097499-A1 | Amide, carbamate, and urea derivatives | ARNOLD MACKLIN BRIAN (US) | 2004-05-20 | — | — | US | disclosed |
| US-6617351-B1 | Amide, carbamate, and urea derivatives | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| EP-0976744-A1 | Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097499-A1 | Amide, carbamate, and urea derivatives | GRIN2A, GLUL, GRIK5 | GRIA4 16/4885CTSL 2458/4885CTSB 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.